- Home
- APRE vs DUO Comparison
APRE vs DUO Comparison
Compare APRE & DUO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- DUO
- Stock Information
- Founded
- APRE 2006
- DUO 2011
- Country
- APRE United States
- DUO China
- Employees
- APRE N/A
- DUO N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- DUO Real Estate
- Sector
- APRE Health Care
- DUO Finance
- Exchange
- APRE Nasdaq
- DUO Nasdaq
- Market Cap
- APRE 15.8M
- DUO 14.6M
- IPO Year
- APRE 2019
- DUO 2019
- Fundamental
- Price
- APRE $3.05
- DUO $0.65
- Analyst Decision
- APRE Strong Buy
- DUO
- Analyst Count
- APRE 2
- DUO 0
- Target Price
- APRE $15.50
- DUO N/A
- AVG Volume (30 Days)
- APRE 22.6K
- DUO 17.4M
- Earning Date
- APRE 11-07-2024
- DUO 08-30-2024
- Dividend Yield
- APRE N/A
- DUO N/A
- EPS Growth
- APRE N/A
- DUO N/A
- EPS
- APRE N/A
- DUO N/A
- Revenue
- APRE $1,310,839.00
- DUO $37,352,654.00
- Revenue This Year
- APRE $134.21
- DUO N/A
- Revenue Next Year
- APRE N/A
- DUO N/A
- P/E Ratio
- APRE N/A
- DUO N/A
- Revenue Growth
- APRE 130.31
- DUO 6.61
- 52 Week Low
- APRE $2.15
- DUO $0.32
- 52 Week High
- APRE $8.85
- DUO $4.67
- Technical
- Relative Strength Index (RSI)
- APRE 43.20
- DUO 44.53
- Support Level
- APRE $3.02
- DUO $0.67
- Resistance Level
- APRE $3.39
- DUO $0.81
- Average True Range (ATR)
- APRE 0.30
- DUO 0.14
- MACD
- APRE -0.01
- DUO 0.02
- Stochastic Oscillator
- APRE 3.85
- DUO 11.77
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. Through its subsidiaries, It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.